Our European CRO offers pharmaceutical, biotech and medtech companies full coverage of Phase II-III and late phase clinical studies for drugs and medical devices in Western and Central Europe through our offices in France and Czech Republic, as well as in Algeria and Israel.
As a well-established high-quality European CRO, Advanced Drug and Device Services (ADDS) Group contributes to successfully bring as early, safely and cost effectively as possible your products to the market in a unique one-stop shop approach for Europe.
ADDS helps you to:
- Conceive your complete development program and risk management plan
- Secure your administrative submissions
- Select the right investigator sites
- Shorten the patient recruitment time
- Improve the patient retention ratio
- Anticipate the risks and solve the issues
- Provide high quality data and reports
- Meet the Regulatory requirements
Fields of expertise
- Drug development
- Oncology
- Central Nervous System (CNS) (eg Alzheimer, neurodenerative diseases, multiple sclerosis, psychiatry)
- Cardiovascular diseases and metabolism
- Orphan Drug
- Medical devices
- Combination Products
- Paediatric Investigation Plan
Description of services
- Consulting
- Phase II/III studies
- Late Phase studies, Phase IV
- Project Management
- Submissions
- Monitoring
- Data Management
- Statistics
- Medical Writing
- Safety
- Risk Management Plan
Geographical coverage
- Western Europe
- Central Europe
- Israel
- Middle East and North African Regions (MENA): Algeria, Morocco, Tunisia, Egypt,…